Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02248051 · ClinicalTrials.gov registry record · Phase 1
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
A Phase 1 study, sponsored by Complexa.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02248051 is a Phase 1 study that has completed, run by Complexa. The registered enrollment target is 12 participants.
The verdict
NCT02248051, a Phase 1 study, has completed, sponsored by Complexa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10, at potentially therapeutic doses, in the target patient population comprised of subjects with Stage 3 and 4 chronic kidney injury (CKI). In addition, associated pharmacodynamic (PD) effects of CXA-10 will be investigated.
Interventions
- DRUG CXA-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02248051
The ClinicalTrials.gov registry entry for NCT02248051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Complexa, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CXA-10 is the first listed.
NCT02248051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02248051 about?
NCT02248051 is a clinical study titled "Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury". The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10, at potentially therapeutic doses, in the target patient population comprised of subjects with Stage 3 and 4 chronic kidney injury (CKI). In addition, associated pharmacodynamic (PD) effects...
What is the current status of trial NCT02248051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02248051?
The interventions under investigation include: CXA-10 (DRUG).
Who is sponsoring clinical trial NCT02248051?
This trial is sponsored by Complexa, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.